Health and Fitness Health and Fitness
Tue, February 14, 2012
[ Tue, Feb 14th 2012 ] - Market Wire
Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
[ Tue, Feb 14th 2012 ] - Market Wire
Titan Medical Inc. Announces Results for Fiscal Year Ended December 31, 2011
[ Tue, Feb 14th 2012 ] - Market Wire
The Ensign Group Announces Addition of New Director
[ Tue, Feb 14th 2012 ] - Market Wire
Jazz Pharmaceuticals to Announce 2011 Full Year a .. th Quarter Financial Results on February 27, 2012
[ Tue, Feb 14th 2012 ] - Market Wire
Kindred Healthcare Recaps Quality Improvements an .. d Issues Quality and Social Responsibility Report
[ Tue, Feb 14th 2012 ] - Market Wire
The Law Firm of Levi &;; Korsinsky Noti .. Their Investment in Health Management Associates
[ Tue, Feb 14th 2012 ] - Market Wire
Sirona Biochem Appoints Three Chemistry Experts to Subsidiary Scientific Advisory Board
[ Tue, Feb 14th 2012 ] - Market Wire
Cytomedix to Present at LHA Life Sciences &;; Medical Technologies Virtual Conference
[ Tue, Feb 14th 2012 ] - Market Wire
Brower Piven Encourages Investors Who Have Losses .. nvestment in Columbia Laboratories, Inc. to Inqui
[ Tue, Feb 14th 2012 ] - Market Wire
Amgen Names Michael Severino, M.D., Senior Vice P .. l Development and Corporate Chief Medical Officer
[ Tue, Feb 14th 2012 ] - Market Wire
Masimo Announces quot;;Better Carequot; .. sk-Share Program for Blood Transfusion Related Co
[ Tue, Feb 14th 2012 ] - Market Wire
Brower Piven Encourages Investors Who Have Losses .. nvestment in BioSante Pharmaceuticals, Inc. to In
[ Tue, Feb 14th 2012 ] - Market Wire
Molina Healthcare Appoints Garrey E. Carruthers to Its Board of Directors
[ Tue, Feb 14th 2012 ] - Market Wire
Natural Alternatives International, Inc. Files Pa .. ngement Claim Against DNP International Co., Inc.
[ Tue, Feb 14th 2012 ] - Market Wire
ViroPharma to Participate in Two Upcoming Healthcare Investor Conferences
[ Tue, Feb 14th 2012 ] - Market Wire
Milberg LLP Announces Class Action Lawsuits Again .. t Associates, Inc.;; Launches Case Website
[ Tue, Feb 14th 2012 ] - Market Wire
Unilens Vision Reports Diluted EPS of $0.12 for Second Quarter of FY2012
[ Tue, Feb 14th 2012 ] - Market Wire
Syneron to Present the New GentleMax Pro(R) at the 2012 South Beach Symposium
[ Tue, Feb 14th 2012 ] - Market Wire
Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
[ Tue, Feb 14th 2012 ] - Market Wire
Obagi Medical Products, Inc. Responds to February .. Its Rights Plan and Corporate Governance Matters
[ Tue, Feb 14th 2012 ] - Market Wire
The Briscoe Law Firm and Powers Taylor, LLP Inves .. Life Sciences, Inc. Concerning the Sale of SRLS t
[ Tue, Feb 14th 2012 ] - Market Wire
Inergetics Announces the Creation of its Advisory Board
[ Tue, Feb 14th 2012 ] - Market Wire
Cannabis Science Signs Multi-Company Acquisition .. Boost Revenues, Its Pharmaceutical Operations and
[ Tue, Feb 14th 2012 ] - Market Wire
Eyeing Critical Insider Trades in Dendreon Corporation
[ Tue, Feb 14th 2012 ] - Market Wire
Thoratec Presentation at Leerink Swann Healthcare Conference to be Webcast
[ Tue, Feb 14th 2012 ] - Market Wire
Product Innovation Drives Record Results for Bond Laboratories
[ Tue, Feb 14th 2012 ] - Market Wire
Array BioPharma Announces Closing of Public Offer .. Common Stock and Exercise of Overallotment Option
[ Tue, Feb 14th 2012 ] - Market Wire
International Drug amp;; Explosives Detect .. orp. Launches Worldwide Retail Marketing Campaign
[ Tue, Feb 14th 2012 ] - Market Wire
International Drug & Explosives Detection Company .. orp. Launches Worldwide Retail Marketing Campaign
[ Tue, Feb 14th 2012 ] - Market Wire
Biogen Idec neemt Stromedix over

Biogen Idec neemt Stromedix over


Published on 2012-02-14 06:50:44 - Market Wire
  Print publication without navigation


WESTON & CAMBRIDGE, Mass.--([ ])--Biogen Idec (NASDAQ: BIIB) en Stromedix, Inc. melden vandaag dat ze een definitieve overeenkomst hebben gesloten.

Biogen Idec neemt Stromedix Inc., een privaat, biotechnologisch bedrijf gericht op innovatieve therapien voor fibrose en orgaanuitval.

Onder de contractvoorwaarden staat dat Biogen Idec een contante vooruitbetaling doet van 75 miljoen dollar en eventuele, aanvullende betalingen doet tot 487 miljoen dollar.

Deze zijn afhankelijk van de resultaten van enkele ontwikkelingssuccessen en goedkeuringsmijlpalen.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

Contributing Sources